Compare Amer Sports Inc (AS) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amer Sports Inc vs Crispr Therapeutics AG — how do they compare? Amer Sports Inc trades at $33.85 (market cap $21.04B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.17B). The key difference: Amer Sports Inc is far larger — about 4.1× Crispr Therapeutics AG's market cap. Which is the better fit depends on your goals.
| AS | CRSP | |
|---|---|---|
Market Cap | $21.04B | $5.17B |
Sector | Technology | Health |
52-Week High | $41.96 | $76.78 |
52-Week Low | $29.54 | $44.34 |
Enterprise Value | $21.36B | $3.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amer Sports (AS) trades at $36.84, up 2.02% today, with a bullish technical signal from moving averages and strong analyst consensus. The company reported robust Q1 2026 results, beating EPS estimates with $0.38 versus $0.31 expected, and raised full-year guidance. Revenue grew 32% year-over-year to $1.95 billion, driven by strength in Arc'teryx and Salomon brands.
Outlook is positive given earnings momentum and raised 2026 guidance, but risks include high valuation (P/E 45.2) and dependence on premium brand sustainability. The consensus price target of $58.67 implies significant upside, supported by 12 buy ratings. Investors should monitor Q2 2026 earnings on August 18 for continued growth validation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amer Sports Inc
Amer Sports is a global group of iconic sports and outdoor brands, including Arc'teryx, Salomon, Wilson, and Atomic. It designs and manufactures high-quality equipment, apparel, and footwear for athletes worldwide.
Read more on AS →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
